Acquired before their SBIR Involvement by Enochian BioSciences (NASDA:ENOB) - itself a small firm focused on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer -- the transaction was structured such that that acquisition did not adversely impact OncoSynergy's SBIR eligibility. OncoSynergy is a clinical-stage immuno-oncology company originally spun out of UCSF and having previously been located in the JLABS South San Francisco incubator. Relocated to CT after the acquisition, the firm more recently is organized around a new class of therapeutics that simultaneously targets multiple hallmarks of cancer progression and that has demonstrated dramatic preclinical efficacy as monotherapy and in strategic combinations. Anchored in the premise that therapy resistance and metastasis are the leading causes of death in cancer, the first area of concentration for Onco Synergy principals is glioblastoma - and aggressive brain cancer.
